Mary Rinella to Metabolic Diseases
This is a "connection" page, showing publications Mary Rinella has written about Metabolic Diseases.
Connection Strength
2.458
-
Variance Between Clinical Guidance and Real-World Management of Metabolic Dysfunction-associated Steatotic Liver Disease in the United States. Clin Gastroenterol Hepatol. 2025 Feb; 23(2):374-376.e3.
Score: 0.827
-
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024 05 01; 79(5):1212-1219.
Score: 0.782
-
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025 Nov; 10(11):998-1012.
Score: 0.222
-
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice. Clin Gastroenterol Hepatol. 2026 Mar; 24(3):633-645.e4.
Score: 0.217
-
Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025 Mar 06; 11(1):14.
Score: 0.214
-
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol. 2024 03; 80(3):419-430.
Score: 0.196